SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending due to rapidly escalating geopolitical tensions in the Middle East following reports of U.S.-Israeli strikes on Iran and subsequent retaliatory actions, with the community actively debating whether crude oil prices will surge higher on potential Strait of Hormuz disruptions or if the rally will prove temporary despite a significant military buildup in the region.

SSgA Active Trust - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

XLE is trending due to U.S. intervention in Venezuela and escalating geopolitical tensions in the Middle East, particularly around the Strait of Hormuz, which is fueling a significant "war risk premium" in oil prices and leading the community to anticipate massive upside for energy stocks.

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product NexoBrid, is an orphan biologic for eschar removal in severe burns. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.

MediWound Ltd

MediWound is trending as investors eagerly anticipate a potential BARDA contract for its burn treatment NexoBrid, which recently showed strong efficacy in blast injuries, alongside promising advancements for its EscharEx chronic wound therapy. This momentum, including institutional interest and buyout speculation, is driving conversation despite polarized views on the stock's ability to break through current trading ranges.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is trending as escalating Middle East geopolitical tensions, including concerns over oil supply chokepoints like the Strait of Hormuz, are fueling community anticipation of surging crude prices and a potential short squeeze for this low-float energy stock.

Fan Tokens allow fans across multiple sports verticals to exercise their share of influence within their favourite teams/leagues/clubs. Through Socios.com, fans are empowered to participate in certain club decisions, for example, choosing a goal celebration song in a football stadium, choosing which fighters should go head to head in MMA, and more. Thanks to Fan Tokens, holders receive access to once-in-a-lifetime experiences such as player meet and greets, training day events &amp; much much more.  The growing list of partnerships launching their Fan Tokens on the Socios.com platform includes some of the biggest sporting organizations in the world such as FC Barcelona, Inter Milan, AC Milan, Manchester City, UFC, ROUSH Fenway Racing, Aston Martin, just to name a few.

Italian National Football Team Fan Token

The iShares U.S. Aerospace & Defense ETF (ITA) is trending amidst heightened global geopolitical tensions, including escalating conflicts in the Middle East and South Asia, prompting community discussion on potential impacts for defense spending and "war stocks." While some anticipate continued strength, others note recent profit-taking and market rotation out of the sector after a significant rally.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevron is trending as intensifying geopolitical tensions in the Middle East, particularly regarding potential oil supply disruptions and the Strait of Hormuz, are driving crude prices higher. The community is actively discussing Chevron's strategic advantages, including expanded access to Venezuelan oil and new global exploration deals, positioning it for potential gains amid these market shifts.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is trending amid enthusiasm for positive Phase 3 clinical trial results for its HER2-positive breast cancer drug and encouraging lung cancer therapy data, fueling community discussions about its oncology pipeline and strategic pivot, even as some debate recent analyst upgrades against news of a partner offloading its stake.

SSgA Active Trust - State Street SPDR Dow Jones Industrial Average ETF Trust

DIA is trending amidst escalating US-Iran geopolitical tensions, characterized by reports of military actions and leadership changes, coupled with market uncertainty following the Supreme Court's tariff ruling and subsequent threats of new tariffs from President Trump. The community is sharply divided between anticipating a potential market rally and fearing a significant downturn due to these events and broader economic concerns.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

The Roundhill Magnificent Seven ETF ($MAGS) is a major talking point as its mega-cap tech holdings exhibit recent underperformance against the broader market, prompting community debate over a potential rotation into other sectors or the unwinding of an AI-driven valuation bubble.

Global X Funds - Global X Silver Miners ETF

The Global X Silver Miners ETF is actively discussed amid a tightening physical silver supply and surging industrial demand from AI and EVs, fueling a "silver squeeze" narrative. Despite current frustration over miners lagging the metal's price surge, the community widely anticipates a significant catch-up rally, viewing the sector as historically undervalued.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What is Lifesci Capital's Estimate for LRMR FY2025 Earnings?

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Equities researchers at Lifesci Capital issued their FY2025 EPS estimates for Larimar Therapeutics in a note issued to investors on Tuesday...

<ul class="summary-bullets"><li>Wall Street looks set for a cautious open despite Nvidia’s strong quarter, with traders focused on China exposure.</li><li>Warner Bros. Discovery is set to report earnings before the bell.&nbsp;</li><li>On the macro front, investors will parse weekly jobless claims at 8:30 a.m. ET.&nbsp;</li></ul>U.S. stock futures were mixed early Thursday, with traders bracing for a choppy session. While AI bellwether Nvidia delivered a blowout earnings report, concerns over its access to the Chinese market, along with disappointing guidance from software giants like Salesforce and C3.ai, are weighing on investor sentiment.Investors will also be watching for developments as the U.S. and Iran hold their latest round of talks in Geneva today amid military threats.&nbsp;As of 3:00 a.m. ET on Thursday, Nasdaq futures were down 0.1%, Dow futures were down 0.2%, and S&amp;P 500 and Russell 2000 futures were flat, with a positive bias.Meanwhile, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, has flipped to ‘bullish’ from ‘neutral’ a day ago, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, has remained ‘bearish’ amid high message volumes.&nbsp;Trending Stocks To WatchNvidia (NVDA):&nbsp;It was the top trending ticker on Stocktwits at the time of writing. The stock pared its gains in after-hours trading as concerns over China's revenue outlook lingered. CFO Colette Kress confirmed that the current forecasts exclude China revenue. This comes even as the chipmaker has secured a license to ship a small number of its less advanced H200 chips to Beijing, subject to inspection and a 25% duty.&nbsp; Netflix (NFLX), Warner Bros Discovery (WBD) &amp; Paramount (PSKY):&nbsp;Investors are closely tracking the developments in the merger drama, with traders speculating that the streamer may walk away from its bid for Warner Bros. Discovery. Paramount has now upped its stakes with a $31/share offer, while Netflix's co-CEO is reportedly heading to White House to discuss the merger’s regulatory issues. Also, keep an eye on WBD, which reports earnings today.&nbsp;Salesforce (CRW):&nbsp;The software giant’s fiscal 2027 revenue guidance missed Wall Street’s expectations, overshadowing its strong Q4 earnings report.&nbsp;C3.ai (AI):&nbsp;A wider-than-expected loss and announcement of workforce cuts is weighing on trader sentiment.&nbsp;Apple (AAPL):&nbsp;Report suggest that the iPhone maker is in talks with major Indian banks to launch its payments service in India by mid-2026.&nbsp;Larimar Therapeutics Inc. (LRMR):&nbsp;The pharma company has priced an upsized $100 million stock offering. The deal was upsized from the earlier-announced $75 million offering and comes after the FDA’s Breakthrough Therapy designation for Nomlabofusp, earlier this week. It was among the top trending tickers on Stocktwits at the time of writing.&nbsp;ImmunityBio Inc. (IBRX):&nbsp;The retail favourite pharma stock remains in focus ahead of the ASCO Genitourinary Cancers Symposium (Feb. 26–28).&nbsp;Watch out for rare-earth stocks in trade today (CRML, MP, UUUU), following a report that suppliers to U.S. aerospace and semiconductor firms are reporting worsening shortages in the market.&nbsp;And copper stocks (FCX, RIO, SCCO, HBM) could see some actiontoday, with copper futures on track for their seventh straight monthly advance.&nbsp; Other tickers trending on Stocktwits at the time of writing included Snap Inc (SNAP), Trade Desk Inc (TTD), Joby Aviation (JOBY), and Sarepta Therapeutics (SRPT), among others.&nbsp;Other Catalysts To WatchOn the economic front, investors will monitor the weekly jobless claims release at 8:30 am. Also, Federal Reserve Vice Chair for Supervision Michelle Bowman is scheduled to testify before Congress later today.&nbsp; On the earnings radar, investors will be watching for the quarterly reports from Warner Bros. Discovery (WBD), Baidu (BIDU), Celsius (CELH), Shake Shack (SHAK), and J.M. Smucker (SJM), among others, before the bell today. Notable companies reporting earnings after market close include Intuit (INTU), Dell Technologies (DELL), TeraWulf (WULF), Rocket Lab (RKLB), and SoundHound AI (SOUN), among others.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Tread Caution On Nvidia’s China Risk: Why NFLX, WBD, AAPL, CRM, AI, LRMR Are On Traders' Radar Today

Data from Stocktwits showed that retail sentiment on SPY and QQQ diverged. 

Equity

<ul class="summary-bullets"><li>The company priced an upsized $100 million stock offering, following a record 61% surge in Wednesday’s regular session.</li><li>On Tuesday, the FDA granted Breakthrough Therapy Designation to Nomlabofusp, Larimar’s frataxin protein replacement therapy for Friedreich’s ataxia.</li><li>The company remains on track to submit a BLA in June and expects topline data in Q2.</li></ul>Shares of Larimar Therapeutics Inc. (LRMR) surged over 60% on Wednesday to their strongest session on record before pricing an upsized $100 million stock offering, extending gains following the FDA’s Breakthrough Therapy designation for Nomlabofusp.<h2 class="st-heading-2">Larimar Prices Upsized $100M Stock Offering</h2>Late Wednesday, the biotech firm said it priced 20 million shares of common stock at $5 per share, raising gross proceeds of nearly $100 million before underwriting discounts and expenses.The deal was upsized from the earlier-announced $75 million offering. Larimar also granted underwriters a 30-day option to purchase up to an additional 3 million shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on Thursday.Larimar intends to use the net proceeds to support the development of Nomlabofusp, its Breakthrough Therapy-designated frataxin protein replacement treatment for a neurodegenerative disorder, as well as working capital and general corporate purposes, including research and development and commercialization expenses.<h2 class="st-heading-2">FDA Grants Breakthrough Status To Nomlabofusp</h2>The equity raise comes just one day after Larimar said that the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-larimar-therapeutics-stock-surge-pre-market-today/cZRvC02R4CO">FDA granted</a> Breakthrough Therapy Designation to Nomlabofusp, its frataxin protein replacement therapy for adults and children with Friedreich’s ataxia, a rare inherited neurodegenerative disorder.The designation is intended to expedite development and regulatory review for therapies that may offer substantial improvement over available treatments.The FDA’s decision was based on preliminary data from Larimar’s ongoing open-label study. The company said treatment raised frataxin levels in patients’ skin to amounts typically seen in people who carry the gene mutation but do not develop symptoms. After one year, patients also showed consistent improvement across four key measures of the disease, including overall neurological function, daily living activities, hand coordination and fatigue.The agency also reaffirmed its willingness to consider skin frataxin levels as a novel surrogate endpoint reasonably likely to predict clinical benefit, supporting Larimar’s planned Biologics License Application (BLA) seeking accelerated approval.<h2 class="st-heading-2">BLA Timeline And Phase 3 Plans Remain On Track</h2>Larimar said it remains on track to submit a BLA in June. Topline data from the open-label study to support the filing are expected in the second quarter of this year.The company also plans to initiate screening in a global confirmatory Phase 3 study in the second quarter of 2026, with first patient dosing expected by mid-2026. If approved, a U.S. launch is targeted for the first half of 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for LRMR was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/lrmr_ss_png_14eb5c6335.webp" alt="lrmr ss.png" width="968" height="143"><figcaption>LRMR sentiment and message volume as of February 25 | Source: Stocktwits</figcaption></figure>One user said, “back at $6 hope to open at $7-$8 tomorrow.”<stembedurl>https://stocktwits.com/Fa07/message/645927469</stembedurl>Another user said, “They’ll get this drug pushed through and the share price will be 15-20 very soon.”<stembedurl>https://stocktwits.com/mrtallman/message/645936108</stembedurl><a href="https://stocktwits.com/symbol/LRMR">LRMR stock</a> has jumped 56% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

LRMR stock has jumped 56% year to date. (Photo credit: Getty Images)

Larimar Prices $100M Stock Sale After Record Rally Fueled By FDA Breakthrough Tag For Protein Replacement Therapy

Larimar (LRMR) company priced 20 million shares at $5 each, upsized from a previously announced $75 million raise.

The company priced 20 million shares at $5 each, upsized from a previously announced $75 million raise.

Best Small Cap Stocks To Follow Today - February 25th

Larimar Therapeutics, AltC Acquisition, XWELL, Direxion Daily PLTR Bear 1X Shares, and Vale are the five Small Cap stocks to watch today, according to MarketBeat's stock screener tool. Small-cap...

Citigroup Increases Larimar Therapeutics (NASDAQ:LRMR) Price Target to $14.00

Citigroup upped their target price on Larimar Therapeutics from $12.00 to $14.00 and gave the stock a "buy" rating in a report on Wednesday...

Larimar Therapeutics (NASDAQ:LRMR) Hits New 1-Year High After Analyst Upgrade

Larimar Therapeutics (NASDAQ:LRMR) Sets New 12-Month High on Analyst Upgrade...

Biotech Stocks To Follow Today - February 25th

ImmunityBio, Larimar Therapeutics, and United Therapeutics are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded...

Larimar Therapeutics Sees Unusually High Options Volume (NASDAQ:LRMR)

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) was the target of some unusual options trading on Wednesday. Traders acquired 3,744 call options on the company. This represents an increase...

Larimar Therapeutics' (LRMR) Outperform Rating Reaffirmed at Wedbush

Wedbush reaffirmed an "outperform" rating and issued a $11.00 price objective on shares of Larimar Therapeutics in a research note on Wednesday...

Lifesci Capital Upgrades Larimar Therapeutics (NASDAQ:LRMR) to "Strong-Buy"

Lifesci Capital upgraded Larimar Therapeutics to a "strong-buy" rating in a research note on Tuesday...

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

LRMR
Larimar Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest LRMR News

LRMRLarimar Therapeutics Inc